Q
Qiagen
Provider of molecular Sample to Insight solutions
About Qiagen
QIAGEN is a global leader in providing molecular testing solutions that enable researchers and clinicians to unlock valuable insights from DNA, RNA, and proteins. Operating in the life sciences and diagnostics markets, QIAGEN serves a diverse range of clients including academic institutions, pharmaceutical companies, and clinical laboratories. The company offers a comprehensive portfolio of products, including sample technologies, assay technologies, and bioinformatics software, designed to streamline the workflow from sample collection to data interpretation.
QIAGEN's business model revolves around the sale of consumables, instruments, and software solutions. The company generates revenue through the direct sale of these products, as well as through service contracts and licensing agreements. By focusing on innovation and customer-centric solutions, QIAGEN aims to address the evolving needs of the molecular biology and diagnostics sectors.
Key products include the QIAseq UPXome RNA Library Kits, which maximize gene expression insights from minimal RNA amounts, and the QIAstat Dx Viral Vesicular Panel, which enhances research and surveillance efforts for viruses like monkeypox. Additionally, QIAGEN offers the QIAstat Dx Analyzer, a fully integrated and scalable digital PCR system that delivers precise results quickly and efficiently.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1984
- Headquarters
- Venlo, Netherlands
- Listing
- IPO 1996
- Employees
- 5,482
- Open positions
- 75
- Dealroom signal
- 67.0/100
- Industry
- Health
- Sector
- Health, Data Analytics, Biotechnology, Oncology, DNA, Genetics and genomics, Molecular
- Technology
- Artificial Intelligence, Big Data, Deep Tech, Machine Learning, Computer Vision
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 21 companies, latest Nov 2025
- Capital deployed
- $61M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO CONVERTIBLE✓Other financing | Sep 2024 | $500M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Aug 2023 | $0 | — | Westpac | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Qiagen is 820K monthly website visits, down 3.5% over the last three months. Qiagen's team grew 1.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Parse BiosciencesSeattle, United StatesProviding researchers with the ability to perform single cell sequencing with single cell whole transcriptome kit
$225Mvaluation
Gentra SystemsMinneapolis, United StatesMolecular testing tools and sample processing technologies
→
GenooxPalo Alto, United StatesA healthcare and technology company on a mission to make clinical genetic sequencing more accessible
$70Mvaluation
VerogenSan Diego, United StatesSequencing solutions for the forensic and human identification markets
$150Mvaluation
NeuMoDx MolecularAnn Arbor, United StatesSolutions for molecular diagnostic (mdx) testing
$80Mvaluation
N-of-OneLexington, United StatesMolecular decision support company providing clinicians with the most concise, accurate and clinically meaningful interpretation of molecular test results
$28Mvaluation
STAT-DxBarcelona, SpainDevelops near-patient testing products for healthcare professionals
$191Mvaluation
Omicsoft CorporationCary, United StatesOmicSoft focus on biomarker data management, visualization, and analysis
→
ExiqonVedbæk, DenmarkSupplier of flexible solutions for RNA research
$100Mvaluation
ProtagenDortmund, GermanyA provider of services, products and software solutions for protein research
$5.4Mvaluation
PrimeraDxMansfield, United KingdomMultiplexed infectious disease assays that include scalable target amplification routine technology
$80Mvaluation
BIOBASEWolfenbüttel, GermanyResources for comprehensive data on published human inherited disease
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
HHS Administration for Strategic Preparedness and Response
US Department of Health and Human Services
US Department of War
Series B and later1 investor entered at this stage
Westpac
Other known investors6 additional known investors
University of Düsseldorf
Bernhard Nocht Institute
Leibniz Association
Mooroolbark Investments
NeoMed
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Qiagen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Qiagen’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.